
Opinion|Videos|August 1, 2024
IPF and PDE4B Inhibitors
Author(s)Steven D. Nathan, MD
Dr Nathan highlights the role of PDE4B inhibitors in IPF management.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What is the rationale for studying the phosphodiesterase 4 (PDE4) inhibitor pathway in idiopathic pulmonary fibrosis (IPF)?
- How do PDE4 inhibitors differ from PDE4B inhibitors?
- Why is this pathway of interest to pulmonologists and patients living with IPF?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Bills to Address Expiring ACA Subsidies Fail to Pass Senate
2
ICYMI: Highlights From SPD 2025
3
Advancing Early Detection and Equitable Access in Alzheimer Disease Care
4
In CLL, New Therapies Offer Potential for Personalized Approaches
5












































